• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在一名肾移植受者中，使用研究性抗生素头孢吡肟/齐德巴坦（WCK 5222）成功治疗了由产新德里金属β-内酰胺酶的铜绿假单胞菌引起的肺感染和颅底骨髓炎。

Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222).

作者信息

Soman Rajeev, Sirsat Rasika, Sunavala Ayesha, Punatar Neha, Mehta Jugal, Rodrigues Camilla, Veeraraghavan Balaji

机构信息

Department of Infectious Diseases, Jupiter Hospital, Pune, India.

Courtesy Visiting Consultant, P. D. Hinduja National Hospital & Medical Research Centre, Mumbai, India.

出版信息

Eur J Clin Microbiol Infect Dis. 2024 Feb 28. doi: 10.1007/s10096-024-04791-1.

DOI:10.1007/s10096-024-04791-1
PMID:38416290
Abstract

A case of sino-pulmonary infection with skull base osteomyelitis due to XDR-Pseudomonas aeruginosa in renal transplant recipient was successfully treated with investigational antibiotic, cefepime/zidebactam (WCK 5222). This case highlights challenges in managing XDR-pseudomonal infection where source control was infeasible, antibiotic options were extremely limited and individualized dose adjustments were needed.

摘要

一名肾移植受者因广泛耐药铜绿假单胞菌感染导致鼻窦肺部感染合并颅底骨髓炎，使用试验性抗生素头孢吡肟/齐他西巴坦（WCK 5222）成功治愈。该病例凸显了在管理广泛耐药铜绿假单胞菌感染时所面临的挑战，即感染源控制不可行、抗生素选择极为有限且需要进行个体化剂量调整。

相似文献

1
Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222).在一名肾移植受者中，使用研究性抗生素头孢吡肟/齐德巴坦（WCK 5222）成功治疗了由产新德里金属β-内酰胺酶的铜绿假单胞菌引起的肺感染和颅底骨髓炎。
Eur J Clin Microbiol Infect Dis. 2024 Feb 28. doi: 10.1007/s10096-024-04791-1.
2
Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report.新型β-内酰胺酶增强剂研究用抗生素头孢吡肟/齐他培南（WCK 5222）治疗产 NDM 广泛耐药铜绿假单胞菌感染所致腹腔感染相关性脓毒症患者的同情用药：一例报告。
Ann Clin Microbiol Antimicrob. 2023 Jul 5;22(1):55. doi: 10.1186/s12941-023-00606-x.
3
Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia.成功使用头孢吡肟-齐多夫定（WCK 5222）作为挽救疗法治疗急性 T 细胞白血病成年患者广泛耐药新德里金属β-内酰胺酶产生铜绿假单胞菌感染的播散性感染。
Antimicrob Agents Chemother. 2023 Aug;67(8):e0050023. doi: 10.1128/aac.00500-23. Epub 2023 Jun 14.
4
Case Commentary: Successful Use of Cefepime/Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Infection in an Adult Patient with Acute T-Cell Leukemia.病例评论：头孢吡肟/齐多夫定（WCK 5222）作为挽救疗法成功治疗成人急性 T 细胞白血病伴广泛耐药新德里金属β-内酰胺酶产 感染播散
Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0066323. doi: 10.1128/aac.00663-23. Epub 2023 Jul 3.
5
Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.从一株耐碳青霉烯铜绿假单胞菌临床分离株中筛选出对 WCK 5222（头孢吡肟/齐他培南）耐药的突变株，并对其进行分子特征分析。
Microbiol Spectr. 2022 Feb 23;10(1):e0267821. doi: 10.1128/spectrum.02678-21.
6
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.WCK 5222（头孢吡肟/齐地卡南）针对产生具有临床相关性β-内酰胺酶的革兰氏阴性菌的抗菌活性测试。
J Antimicrob Chemother. 2017 Jun 1;72(6):1696-1703. doi: 10.1093/jac/dkx050.
7
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.WCK 5107（齐德巴坦）和WCK 5153是新型PBP2抑制剂，对铜绿假单胞菌表现出强大的“β-内酰胺增强剂”活性，包括产多重耐药金属β-内酰胺酶的高风险克隆株。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02529-16. Print 2017 Jun.
8
and Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae.β-内酰胺类药物与新型β-内酰胺酶增强剂齐他培南和 WCK 5153 联合应用对产金属β-内酰胺酶多重耐药肺炎克雷伯菌的活性。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00128-19. Print 2019 May.
9
Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.头孢吡肟、齐多夫定和联合制剂（WCK 5222）在中性粒细胞减少性肺炎小鼠模型中对耐多药铜绿假单胞菌的人模拟支气管肺部暴露的疗效。
J Antimicrob Chemother. 2020 Jan 1;75(1):149-155. doi: 10.1093/jac/dkz414.
10
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.WCK 5222（头孢吡肟-齐地巴坦）对2015年全球收集的革兰氏阴性菌临床分离株的抗菌活性。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.00072-17. Print 2017 May.

引用本文的文献

1
Cefepime-zidebactam therapy for extensively drug-resistant and infection as a bridge to liver transplantation.头孢吡肟-齐多夫定治疗广泛耐药感染作为肝移植的桥梁。
JAC Antimicrob Resist. 2025 Jul 17;7(4):dlaf129. doi: 10.1093/jacamr/dlaf129. eCollection 2025 Aug.
2
From genomics to treatment: overcoming pan-drug-resistant in clinical settings.从基因组学到治疗：克服临床环境中的泛耐药性
Front Pharmacol. 2025 May 30;16:1570278. doi: 10.3389/fphar.2025.1570278. eCollection 2025.
3
In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.

本文引用的文献

1
Transcending the challenge of evolving resistance mechanisms in through β-lactam-enhancer-mechanism-based cefepime/zidebactam.通过基于β-内酰胺增强机制的头孢吡肟/齐他培南克服不断进化的耐药机制的挑战。
mBio. 2023 Dec 19;14(6):e0111823. doi: 10.1128/mbio.01118-23. Epub 2023 Oct 27.
2
Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report.新型β-内酰胺酶增强剂研究用抗生素头孢吡肟/齐他培南（WCK 5222）治疗产 NDM 广泛耐药铜绿假单胞菌感染所致腹腔感染相关性脓毒症患者的同情用药：一例报告。
Ann Clin Microbiol Antimicrob. 2023 Jul 5;22(1):55. doi: 10.1186/s12941-023-00606-x.
3
新型抗菌剂对金属β-内酰胺酶产生菌的体外活性及耐药机制
Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1041-1068. doi: 10.1007/s10096-025-05080-1. Epub 2025 Mar 10.
4
Difficult-to-Treat Infections in Critically Ill Patients: A Comprehensive Review and Treatment Proposal.重症患者难治性感染：综述与治疗建议
Antibiotics (Basel). 2025 Feb 11;14(2):178. doi: 10.3390/antibiotics14020178.
5
New antibiotics in clinical pipeline for treating infections caused by metallo-β-lactamases producing Gram-negative bacteria.临床研发中的新型抗生素，用于治疗产金属β-内酰胺酶的革兰氏阴性菌感染。
Curr Opin Infect Dis. 2024 Dec 1;37(6):582-588. doi: 10.1097/QCO.0000000000001056. Epub 2024 Sep 12.
Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia.成功使用头孢吡肟-齐多夫定（WCK 5222）作为挽救疗法治疗急性 T 细胞白血病成年患者广泛耐药新德里金属β-内酰胺酶产生铜绿假单胞菌感染的播散性感染。
Antimicrob Agents Chemother. 2023 Aug;67(8):e0050023. doi: 10.1128/aac.00500-23. Epub 2023 Jun 14.
4
Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.2018 - 2021年抗菌药物检测领导力与监测（ATLAS）项目结果显示，在印度，头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦和美罗培南/法硼巴坦对耐碳青霉烯类铜绿假单胞菌的体外活性较差。
J Infect. 2023 Jul;87(1):e1-e4. doi: 10.1016/j.jinf.2023.04.013. Epub 2023 Apr 24.
5
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.头孢地尔在 CREDIBLE-CR 和 APEKS-NP 三期随机研究中治疗产金属β-内酰胺酶病原体感染。
Clin Infect Dis. 2022 Sep 29;75(6):1081-1084. doi: 10.1093/cid/ciac078.
6
Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression.治疗期间大肠杆菌中头孢地尔耐药性的逐步发展与blaNDM - 5拷贝数和基因表达的增加有关。
Clin Infect Dis. 2022 Aug 24;75(1):47-54. doi: 10.1093/cid/ciab888.
7
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia.肺部药物动力学：机械通气肺炎患者头孢地尔的体内过程。
J Antimicrob Chemother. 2021 Oct 11;76(11):2902-2905. doi: 10.1093/jac/dkab280.
8
Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.β-内酰胺/替加环素（VNRX-5133）联合用药对碳青霉烯类耐药革兰氏阴性菌的活性。
J Antimicrob Chemother. 2021 Jan 1;76(1):160-170. doi: 10.1093/jac/dkaa391.
9
Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria.头孢他啶美罗培南复方制剂（cefiderocol）对多重耐药革兰氏阴性菌的活性。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.01582-20.
10
Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems.WCK 5222（头孢吡肟-齐德巴坦）对全球收集的对碳青霉烯类不敏感的革兰氏阴性杆菌的活性。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.01432-20.